Hightide Therapeutics Inc (HK:2511)
:2511
Want to see HK:2511 full AI Analyst Report?
2511 Stock Chart & Stats
HK$3.05
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$3.05
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.80 - HK$4.72
Previous CloseN/A
Volume82.00K
Average Volume (3M)1.41M
Market Cap
HK$2.05B
Enterprise ValueHK$1.96B
Total Cash (Recent Filing)HK$467.01M
Total Debt (Recent Filing)HK$99.47M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding571,325,700
10 Day Avg. Volume641,080
30 Day Avg. Volume1,410,076
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.14
Price to Sales (P/S)0.00
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.80Price Target Upside90.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetThe shift to positive equity and a debt-to-equity near 0.41 indicates materially improved solvency versus prior years. This durable improvement reduces refinancing risk, gives management more strategic flexibility for R&D or partnerships, and lengthens runway absent immediate revenue.
Improving Cash Flow TrendA reduction in the magnitude of negative free cash flow in 2025 signals improving capital efficiency. While still cash burning, a durable trend toward smaller deficits lowers near-term financing needs and supports the feasibility of moving programs nearer to commercialization with less dilution.
Focused Therapeutic StrategyConcentrated expertise in metabolic disease provides a clear strategic focus and potential competitive differentiation. Structural demand for metabolic therapies is persistent; a specialized pipeline can improve trial design, partnerability, and long-term commercial clarity versus unfocused small biotechs.
Bears Say
No RevenueAbsence of reported revenue means the company has not yet proven commercial viability and remains fully pre-revenue. Over the medium term this maintains dependence on financing, prevents operating leverage, and leaves future cash generation and profitability highly uncertain.
Persistent LossesSustained operating and net losses, including very large 2023 losses and sizable 2025 deficits, imply continued absorption of capital before breakeven. This reduces retained earnings, limits reinvestment capacity, and heightens dilution or refinancing risk if product milestones are delayed.
Ongoing Cash Burn & Funding RelianceContinuous negative operating and free cash flow forces reliance on external capital to sustain R&D and operations. Over a multi-month horizon this structural funding dependence raises execution risk, especially if capital markets tighten or partner deals are delayed.
Hightide Therapeutics Inc News
2511 FAQ
What was Hightide Therapeutics Inc’s price range in the past 12 months?
Hightide Therapeutics Inc lowest stock price was HK$1.80 and its highest was HK$4.72 in the past 12 months.
What is Hightide Therapeutics Inc’s market cap?
Hightide Therapeutics Inc’s market cap is HK$2.05B.
When is Hightide Therapeutics Inc’s upcoming earnings report date?
Hightide Therapeutics Inc’s upcoming earnings report date is Sep 01, 2026 which is in 116 days.
How were Hightide Therapeutics Inc’s earnings last quarter?
Hightide Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -HK$0.268 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.268.
Is Hightide Therapeutics Inc overvalued?
According to Wall Street analysts Hightide Therapeutics Inc’s price is currently Undervalued.
Does Hightide Therapeutics Inc pay dividends?
Hightide Therapeutics Inc does not currently pay dividends.
What is Hightide Therapeutics Inc’s EPS estimate?
Hightide Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hightide Therapeutics Inc have?
Hightide Therapeutics Inc has 571,325,700 shares outstanding.
What happened to Hightide Therapeutics Inc’s price movement after its last earnings report?
Hightide Therapeutics Inc reported an EPS of -HK$0.268 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of Hightide Therapeutics Inc?
Currently, no hedge funds are holding shares in HK:2511
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hightide Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$5.80 (90.16% Upside)
HK$5.80 (90.16% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
273.21%
12-Months-Change
Fundamentals
Return on Equity
-39.41%
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
Hightide Therapeutics Inc
HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its lead product candidate is HTD1801, a gut-liver anti-inflammatory metabolic modulator that targets metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug for the treatment of alcoholic hepatitis; HTD1804 to treat obesity; HTD1805, a multifunctional small molecule drug for the treatment of metabolic diseases; and HTD2802 for the treatment of inflammatory bowel disease. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.
2511 Stock 12 Month Forecast
Average Price Target
HK$5.80
▲(90.16% Upside)
Technical Analysis
CANbridge Pharmaceuticals Inc.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―
Cutia Therapeutics
―
Options Prices
Currently, No data available
---